Item 2.02. Results of Operations and Financial Condition.
On March 6, 2023, Immuneering Corporation (the “Company”) announced its
financial results for the quarter and full-year ended December 31, 2022 and
provided business updates. The full text of the press release issued in
connection with the announcement is furnished as Exhibit 99.1 to this Current
Report on Form 8-K (the “Current Report”).
The information in this Item 2.02 of this Current Report, including Exhibit
99.1, is intended to be furnished and shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as expressly provided by specific
reference in such a filing.
Item 7.01. Regulation FD Disclosure.
On March 6, 2023, the Company posted an updated corporate slide presentation in
the “For Investors” portion of its website at http://www.immuneering.com. A copy of the
slide presentation is furnished as Exhibit 99.2 to this Current Report on Form
8-K.
The information in this Item 7.01 of this Current Report, including Exhibit
99.2, is intended to be furnished and shall not be deemed “filed” for purposes
of Section 18 of the Exchange Act, or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act or the Exchange Act, except as expressly provided by
specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibits relate to Items 2.02 and 7.01, which shall be deemed to
be furnished, and not filed:
Exhibit No. Description 99.1 Press Release issued on March 6, 2023 Immuneering Corporation Corporate Slide Presentation as of March 6, 99.2 2023 Cover Page Interactive Data File (embedded within the Inline XBRL 104 document)
© Edgar Online, source Glimpses